苑东生物: 苑东生物：2024年度环境、社会及公司治理报告

Core Viewpoint - The report highlights the commitment of Yuan Dong Bio to sustainable development through a robust ESG (Environmental, Social, and Governance) framework, emphasizing innovation, compliance, and social responsibility in the pharmaceutical industry [1][2][3]. Group 1: Company Overview - Yuan Dong Bio is dedicated to patient-centered healthcare, focusing on innovation and quality in drug development, with a significant portion of revenue allocated to R&D, exceeding 20% [2][3]. - The company has established a comprehensive governance structure, including a board of directors and various committees to ensure effective decision-making and compliance with regulations [4][5]. Group 2: ESG Commitment - The company integrates ESG principles into its core strategy, aiming for a harmonious balance between environmental sustainability, social responsibility, and corporate governance [1][5]. - Yuan Dong Bio has implemented a three-tier ESG governance structure, comprising the board, an ESG management committee, and an execution team, to oversee and enhance its sustainability initiatives [5]. Group 3: Innovation and Development - The company has a strong focus on innovation, with over 80 ongoing projects, including 18.3% dedicated to new drug development, and has achieved significant milestones in clinical trials [3][5]. - Yuan Dong Bio has successfully launched multiple high-end pharmaceutical products, including 8 domestic first generic products and 14 active pharmaceutical ingredients that meet international standards [3][4]. Group 4: Social Responsibility - The company actively engages in community support initiatives, including healthcare assistance and educational programs, reflecting its commitment to social responsibility and public health [2][5]. - Yuan Dong Bio emphasizes employee welfare and development, recognizing its workforce as a vital asset, and has implemented various programs to support employee growth and well-being [2][5].